We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Prostate
6016
Digital Poster
Clinical
Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation
Giulio Francolini, Italy
PO-1316
Prostate Cancer Patient Reported Outcome After Cyberknife Robotic Radiosurgery
Sebastian Exner, Germany
PO-1317
salvage treatment outcomes in lymph node-positive prostate cancer patients after surgery
Dowook Kim, Korea Republic of
PO-1318
Early Health Economic Analysis of 1.5T MRI-guided Radiotherapy for Localized Prostate Cancer
Charisma Hehakaya, The Netherlands
PO-1319
Infectious Risk After Prostatic Transrectal Fiducial Marker Implantation in Radiation Therapy
Thomas Reynaud, Canada
PO-1320
Clinical outcome of MRI based high-dose-rate brachytherapy for prostate cancer
Simon Buus, Denmark
PO-1322
Low toxicity in LDR brachytherapy boost with real time intraoperative planning in prostate cancer
Marta Barrado Los Arcos, Spain
PO-1323
dose-volume correlation of pelvic bone normal tissue and hematocrit in patients with prostate cancer
Panos Papanikolaou, USA
PO-1324
Factors that influence urinary incontinence correction results after prostatectomy and radiotherapy
Nuria Azahara Linares Mesa, Spain
PO-1325
Dosimetric and clinical impact of rectal spacers in patients undergoing VMAT-IGRT in prostate cancer
Eoin O'Neill, Ireland
PO-1326
Prostate cancer radiotherapy in a COVID-19 pandemic year: experience of a chilean public hospital
Hernan Letelier, Chile
PO-1327
VMAT-SIB boost to the dominant intraprostatic lesion: preliminary results of a dose escalation trial
Paolo Bonome, Italy
PO-1328
Longterm Biochemical Recurrence-Free Survival after PSMA-PET/CT–Based Salvage Radiotherapy
Sonja Adebahr, Germany
PO-1329
Radiotherapy toxicity in prostate cancer patients with bilateral hip prostheses
Andrea Fischer, United Kingdom
PO-1330
SBRT prostate cancer boost of 9 Gy, prospective phase II trial.
Ferran Ferrer Gonzalez, Spain
PO-1331
OLI-P trial: pattern of progression after radiotherapy in PSMA-PET positive METs of prostate cancer
Tobias Hölscher, Germany
PO-1332
Efficacy of stereotactic radiation therapy for the treatment of nodal oligorecurrent prostate cancer
Salvatore Cozzi, Italy
PO-1333
Early Salvage Radiotherapy In the post RADICALS-RT Era: The Gap From Trials to Reality
María Fernanda Sánchez, Chile
PO-1334
PSMA-PET impact on post-prostatectomy recurrencies multidisciplinary management: focus on RT
Valeria Chiofalo, Italy
PO-1335
Salvage HDR brachytherapy for localised recurrent prostate cancer after primary irradiation
Magdalena Stankiewicz, Poland
PO-1336
LONG FOLLOW UP OF LATE TOXICITY AFTER HYPOFRACTIONATED POSTOPERATIVE RADIATION IN PROSTATE CANCER
Jeannette Valero , Spain
PO-1337
Does frailty influence treatment intent in men with non-metastatic prostate cancer?
Katie Connors, United Kingdom
PO-1338
Estimated late toxicities with pelvic nodal irradiation in prostate cancer: Protons vs Tomotherapy
Sham Sundar, India
PO-1339
Prostate cancer reirradiation with stereotactic V-MAT IGRT : interim analysis of a phase II trial.
Alessandro Di Marzo, Italy
PO-1340
SBRT for Japanese patients with prostate cancer: prediction of acute genitourinary toxicities
Makoto Ito, Japan
PO-1341
Trends and predictors of worsening at RT end of anxiety and depression during RT for prostate cancer
Domenico Cante, Italy
PO-1342
Dose-escalated stereotactic radiotherapy for prostate cancer: A feasibility study using a rectal spacer and urethral sparing
Ron Lewin, Israel
PO-1343
Preliminary results of Phase II trial on Carbon-ion boost followed by IMRT for high risk PCa
Filippo Patti, Italy
PO-1344
Symptoms affecting Emotional, Systemic and Social Domains 2 years after RT for prostate cancer
ELISABETTA GARIBALDI, Italy
PO-1345
Systematic Review of Salvage Reirradiation Options for Locally Recurrent Prostate Cancer
Finbar Slevin, United Kingdom
PO-1346
Prostate cancer RT pattern of practice in Italy between 2004-2011: an analysis by the AIRO database
Alessio Bruni, Italy
PO-1347
Urethral sparing increases the therapeutic ratio in dose escalated hypofractionated radiotherapy
Simon KB Spohn, Germany
PO-1348
Separation and rectal dosimetry with a pre-rectal spacer inserted during prostate HDR brachytherapy
Reena DAVDA, United Kingdom
PO-1349
SBRT FOR LOCALIZED PROSTATE CANCER: THERE IS STILL A ROLE FOR ANDROGEN DEPRIVATION THERAPY?
Marco Lorenzo Bonù, Italy
PO-1350
Patterns of local relapse following tumor-targeted dose escalation for localized prostate cancer
Jerusha Padayachee, New Zealand
PO-1351
Rectal spacing hydrogel - significant improvements in LDR prostate brachytherapy dosimetry
Sheel Mehta, United Kingdom
PO-1352
Postoperative hypofractionated RT for prostate adenocarcinoma: results from a large series
Luca Nicosia, Italy
PO-1353
Time Dependence of PSADT prognostic threshold in men treated with post-prostatectomy salvage RT
Cesare Cozzarini, Italy
PO-1354
Finding safe dose-volume constraints for re-irradiation of intraprostatic prostate cancer relapse.
Matteo Augugliaro, Italy
PO-1355
Dose constraints validation in moderate hypofractionation in localized prostate cancer
Xavier Maldonado, Spain
PO-1356
LDR-Brachytherapy vs SBRT: PSA kinetics and toxicity outcomes in localized prostate carcinoma
Maria Cerrolaza, Spain
PO-1357
Does brachytherapy boost improve biochemical control in intermediate and high-risk prostate cancer?
Marcin Miszczyk, Poland
PO-1358
PORT impact on biochemical recurrence in pN1 PCa patients: establishing the appropriate RT timing
Giulia Marvaso, Italy
PO-1359
Are the practices of Radiation oncologists harmonious for hormone therapy in prostate cancer?
Nejla Fourati, Tunisia
PO-1360
Patterns of care for intermediate-risk prostate cancer – results from an online survey
Virgínia Mareco, Portugal
PO-1361
The prognostic value of PI-RADS score in ultra-hypofractionated radiotherapy for prostate cancer.
Marcin Miszczyk, Poland
PO-1362
Prediction of urinary toxicity after prostate cancer RT: long term evaluation
Tiziana Rancati, Italy
PO-1363
Bleeding Risk after Prostate SBRT in Men on Baseline Anticoagulant/Antiplatelet Therapy
Abigail Pepin, USA
PO-1364
Real time dynamic LDR Brachytherapy boost to external beam radiotherapy in prostate cancer
Samantha Forner, United Kingdom
PO-1365
Pattern of recurrence after SBRT in prostate cancer patients with nodal pelvic relapse
Giulio Francolini, Italy
PO-1366
Hypofractionated radiotherapy in prostate cancer older than 70 years
María del Carmen SALAS BUZON, Spain
PO-1367
What is clinically important in the pathology specimen for radical radiotherapy in prostate cancer?
Wojciech Majewski, Poland
PO-1368
HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
ELENA MORENO OLMEDO, United Kingdom
PO-1369
Updated prospective study of MR-guided focal salvage HDR brachytherapy for recurrent prostate cancer
Hans Chung, Canada
PO-1370
SALVAGE-EXTERNAL BEAM RADIOTHERAPY (S-EBRT) FOR RECURRENT PROSTATE CANCER AFTER LDR-BRACHYTHERAPY
Oscar Muñoz Muñoz, Spain
PO-1371
First institutional analysis between ultra vs moderate hypofractionated regimens in prostate cancer
Gustavo Ferraris, Argentina
PO-1372
Targeted biopsies are redundant in mp-MRI and PSMA-PET proven radiorecurrent prostate cancer
Marnix Rasing, The Netherlands
PO-1373
MR-guided SBRT for localized prostate cancer: the first results from the MOMENTUM study
Frederik Teunissen, The Netherlands
PO-1374
Feasibility of neurovascular sparing MR-guided adaptive radiotherapy for prostate cancer
Frederik Teunissen, The Netherlands
PO-1375
Preliminary mono-institutional report of prostate/prostate bed SBRT re-irradiation
Francesco Cuccia, Italy
PO-1376
Dosimetric study of scanning method for prostate cancer patients in comparison with wobbler and VMAT
Masru Takagi, Japan
PO-1377
Metastasis-directed therapy for oligorecurrent prostate cancer: a pooled analysis
Piet Ost, Belgium
PO-1378
Patient- vs. physician reported morbidity following radiotherapy of high-risk prostate cancer
Stine Elleberg Petersen, Denmark
PO-1379
Adjuvant radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
Silvia Bisello, Italy
PO-1380
Toxicity outcomes of salvage versus adjuvant radiotherapy for prostate cancer using VMAT and IMRT
David Fasciolo , Italy
PO-1381
A systematic review regarding outcomes and toxicities of re-irradiation for prostate cancer
Consuelo Rosa, Italy
PO-1382
Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma
Angel Montero, Spain
PO-1383
Salvage radiotherapy for locally recurrent prostate cancer after high-intensity focused ultrasound
Nicolas Jullian, Belgium
PO-1384
PSA BOUNCE AND BIOCHEMICAL FAILURE ANALYSIS IN LOW DOSE RATE IODINE-125 PROSTATE BRACHYTHERAPY BOOST
Núria Bultó Boqué, Spain
PO-1385
Treatment compliance to linac-based prostate SBRT using real-time electromagnetic tracking
Raffaella Lucchini, Italy
PO-1386
Diffusion MRI as an early response marker in management of high-risk non-metastatic prostate cancer
Reena DAVDA, United Kingdom
PO-1387
1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs
Francesco Cuccia, Italy
PO-1388
Interrater agreement in contouring the neurovascular bundle and internal pudendal artery for MRgRT
Frederik Teunissen, The Netherlands
PO-1389
Intra-fraction prostate motion during stereotactic irradiation in 1st irradiation and re-irradiation
Alexandre TAILLEZ, France
PO-1390
Curative radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
Silvia Bisello, Italy
PO-1391
Salvage radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
Silvia Bisello, Italy
PO-1392
ARTO (NCT03449719), quality of life monocentric report after stereotactic treatment and abiraterone
Giulio Francolini, Italy
PO-1393
Stereotactic body radiotherapy for prostate cancer lymph node metastases: a systematic review
Alice Zamagni, Italy
PO-1394
Post-prostatectomy ultra-hypofractionated SBRT: preliminary results of a phase II trial
Angel Montero, Spain
PO-1395
CBCT-guided online adaptive radiotherapy: results of the first fifty prostate cancer patients
Lisanne Zwart, The Netherlands
PO-1396
Differences between various rectal volumes and implications for patient-reported rectal toxicity
Niclas Pettersson, Sweden
PO-1397